Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935721 | 0.78 | MAPT (0.43) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| SCHEMBL11557617 | 0.78 | LMNA (0.38) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| Bromide SCHEMBL2954210 | 0.77 | MAPT (0.42) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| Bromide SCHEMBL27876873 | 0.77 | MAPT (0.42) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL27306778 | 0.77 | MAPT (0.42) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL11555121 | 0.77 | LMNA (0.35) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| SCHEMBL27843501 | 0.73 | MEN1 (0.56) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| SCHEMBL8868709 | 0.72 | MAPT (0.42) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| SCHEMBL16765743 | 0.70 | HTT (0.50) | LMNAHSD17B3MAPTKMT2AMEN1 | |
| SCHEMBL27509200 | 0.70 | MEN1 (0.49) | LMNAMAPTKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| EP-1513520-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2004-03-18 | — | — | US | disclosed |
| WO-2003103663-A2 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | LMNA 3752/4885HSD17B3 3552/4885MAPT 2315/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | LMNA 3752/4885HSD17B3 3552/4885MAPT 2315/4885 |
| US-20040054180-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | LMNA 3752/4885HSD17B3 3552/4885MAPT 2315/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | LMNA 3752/4885HSD17B3 3552/4885MAPT 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.